Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared a post by Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, on X, adding:
“Bispecific antibodies are improving RRMM outcomes—but early mortality remains high
- 34% of 441 real-world patients died within 12 months (median 2.9 months)
- Main cause: disease progression (72%)
- Infections contributed to 13%
- 82% had active disease at death
Quoting Mohamed Benlazar‘s post:
“Early mortality with bispecific antibody therapy in RRMM:
an IMWG immunotherapy database real-world analysis here.”
Other articles featuring Mostafa Faisal on OncoDaily.